International panel will discuss latest cannabis science and research, product innovation and organizational growth strategies
TORONTO, Aug. 13, 2018 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN), a Canadian integrated medical cannabis company with its core operations in Colombia, announced today that Company co-founder and CEO Mr. Alvaro Torres will participate in an international panel session at the MJBizCon INT'L marijuana business conference, taking place at the Metro Toronto Convention Centre, Aug. 14th – 16th. Mr. Torres will participate in the How to Use Science and Research to Boost Your Business panel session on Thurs., Aug. 16th at 2:00 p.m.
Mr. Torres states, "At Khiron we are actively engaging with doctors across Latin America to help them better understand alternative treatments for the medical conditions that are most prevalent in our markets and which can have the most positive social impacts. We see the number of doctors willing to prescribe medical cannabis treatments increasing as the body of supporting scientific research grows, with conferences such as this helping further that mission."
With the Company's recently announced LOI to acquire the Latin American Institute of Neurology and the Nervous System ("ILANS"), one of the most respected, fastest growing and largest health provider networks in Colombia and Latin America, Khiron continues to expand its learning platforms to increase doctor awareness about medical cannabis, driving prescriptions and patient acquisition."
Of the six million potential patients in Colombia with conditions that can be helped with medical cannabis, almost half are suffering from chronic neuropathic pain, a condition where Khiron has worked with physician communities throughout Latin America to drive scientific research into the benefits of medical cannabis. The Company has received endorsements from both the Colombian Neurological Association and the Colombian Association of Internal Medicine as it also focuses on treatments for epilepsy, depression and anxiety.
Mr. Torres says, "Going forward, we expect to be leading new rounds of medical cannabis research to improve product quality, evaluate new conditions for treatment, and enhance delivery technologies, and it will all be done with the full buy-in of the Latin American medical community."
About Khiron Life Sciences Corp.
Khiron Life Sciences Corp. (TSXv: KRHN) ("Khiron" or the "Company") is positioned to be the dominant integrated medical cannabis company in Latin America. Khiron has core operations in Colombia and is fully licensed in the country for the cultivation, production, domestic distribution, and international export of both tetrahydrocannabinol (THC) and cannabidiol (CBD) medical cannabis. In May 2018, Khiron listed on the TSX Venture Exchange, becoming the first Colombian based medical cannabis company to trade on any exchange globally.
With a focused regional strategy and patient oriented approach, the Company combines global scientific expertise, agricultural advantages, branded product market entrance experience and education to drive prescription and brand loyalty to address priority medical conditions such as chronic pain, epilepsy, depression and anxiety in the Latin American market of over 620 million people. Khiron is led by Co-founder and Chief Executive Officer, Alvaro Torres, together with an experienced executive team, and a knowledgeable Board of Directors that includes former President of Mexico, Vicente Fox.
Further information on Khiron Life Sciences can be found at www.khiron.ca.
This press release may contain certain forward-looking information and statements ("forward-looking information") within the meaning of applicable Canadian securities legislation, that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts" and other similar expressions. Readers are cautioned to not place undue reliance on forward-looking information. Actual results and developments may differ materially from those contemplated by these statements. Khiron undertakes no obligation to comment analyses, expectations or statements made by third-parties in respect of Khiron, its securities, or financial or operating results (as applicable). Although Khiron believes that the expectations reflected in forward-looking information in this press release are reasonable, such forward-looking information has been based on expectations, factors and assumptions concerning future events which may prove to be inaccurate and are subject to numerous risks and uncertainties, certain of which are beyond Khiron's control, including the risk factors discussed in Khiron's Filing Statement which is available on Khiron's SEDAR profile at www.sedar.com. The forward-looking information contained in this press release is expressly qualified by this cautionary statement and are made as of the date hereof. Khiron disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise.
Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release.
SOURCE Khiron Life Sciences Corp.
For further information: Investor Contacts: Chris Naprawa, President, T: +1 (416) 705-1144, E: [email protected]; Darren Collins, Chief Financial Officer, T: +1 (705) 527-3564, E: [email protected]; Media Contact: Jon Packer, Vice President, Communications, T: +1 (416) 543-9179, E: [email protected]